Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM001 plus UDCA in primary biliary cholangitis
2013-000482-36Phase 2Completed
- Sponsor
- Lumena Pharmaceuticals
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing LUM001 + ursodeoxycholic acid with Placebo + ursodeoxycholic acid (2 arms). Primary endpoint: Change from baseline to Week 13 in pruritus. Started May 2013; status: completed.
02
Drugs
maralixibat
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2013-000482-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000482-36.